Ezra Friedberg Sells 558 Shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $26.09, for a total transaction of $14,558.22. Following the completion of the transaction, the director owned 81,042 shares of the company’s stock, valued at $2,114,385.78. The trade was a 0.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 13.8%

Shares of PTHS stock opened at $28.00 on Thursday. The stock has a market cap of $97.44 million, a PE ratio of -1.36 and a beta of 3.10. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41. The company’s 50 day simple moving average is $26.83. Pelthos Therapeutics Inc. has a 12 month low of $16.09 and a 12 month high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The business had revenue of $10.91 million for the quarter. On average, equities analysts predict that Pelthos Therapeutics Inc. will post -12.63 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Cantor Fitzgerald began coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Oppenheimer upped their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the company an “outperform” rating in a research report on Friday, May 15th. Finally, Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $55.80.

Institutional Investors Weigh In On Pelthos Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC boosted its stake in Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after buying an additional 193,307 shares during the period. Boothbay Fund Management LLC increased its stake in Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the last quarter. J. Goldman & Co LP bought a new position in Pelthos Therapeutics in the 4th quarter worth about $2,418,000. Cantor Fitzgerald L. P. purchased a new stake in shares of Pelthos Therapeutics in the 4th quarter valued at about $1,085,000. Finally, Diadema Partners LP boosted its position in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock valued at $775,000 after acquiring an additional 14,502 shares during the last quarter. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).